Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease

Clinical Nuclear Medicine

Volumn 31, Issue 10, 2006, Pages 605-610

  Coronado, Mónica ^a   Redondo, Andrés ^a   Coya, Juan ^a   Espinosa, Enrique ^a   Couto, Rosa Ma ^a   Zamora, Pilar ^a   Marin, Ma Dolores ^a   Castelo, Beatriz ^a   Lillo, Ma Eugenia ^a   Frutos, Laura ^a   Barón, Manuel González ^a   Curto, Luis M Martín ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Bone metastases; Bone pain; Cancer; Radionuclide therapy; Sm 153

Indexed keywords

LEXIDRONAM SAMARIUM SM 153;

ADULT; AGED; ANALGESIA; ARTICLE; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MALE; RETROSPECTIVE STUDY; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33748912142     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000238304.08812.c1     Document Type: Article

References (25)

1. Silberstein EB. Systemic radiopharmaceutical therapy of painful osteoblastic metastases. Semin Radiat Oncol. 2000;3:240-249.
2. Serafini AN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiat Oncol Biol Phys. 1994;30:1187-1194.
3. Mc Ewan AJ. Use of radionuclides for palliation of bone metastases. Semin Radiat Oncol. 2000;10:103-114.
4. Silberstein EB, Eugene L, Saenger SR. Painful osteoblastic metastases: the role of nuclear medicine. Oncology (Huntingt). 2001;15:157-163.
5. 186Re-HEDP as bone therapeutic radiopharmaceuticals. Nucl Med Biol. 1987;14:223-232.
6. Porter AT, Ben-Josef E, Davis L. Systemic administration of new therapeutic radioisotopes, including phosphorus, strontium, samarium, and rhenium. Curr Opin Oncol. 1994;6:607-610.
7. Goeckeler WF, Edwards B, Volkert WA, et al. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med. 1987;28:495-504.
8. Pons F, Fuster D, Vidal-Sicart S. Tratamiento paliativo del dolor óseo metastásico. Rev Esp Med Nuclear. 2003;22:429-438.
9. Singh A, Holmes RA, Farhangi M, et al. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med. 1989;30:1814-1818.
10. 153Sm radiotherapeutic bone agents. Nuc Med Biol. 1986;13:479-482.
11. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-bind placebo-control clinical trial. J Clin Oncol. 1998;16:1574-1581.
12. 153Sm-Ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33:1583-1591.
13. Sartor O, Quick D, Reid R, et al. A double blind placebo controlled study of 153 samarium EDTMP for palliation of bone pain in patients with hormone refractory prostate cancer [Abstract]. J Urol. 1997;157:321.
14. de Camargo Etchebehere EC, Pereira Neto CAC, Lopes de Lima MC, et al. Treatment of bone pain secondary to metastases using samarium-153-EDTMP. Sao Paolo Med J. 2004;22:208-212.
15. 153Sm-EDTMP for bone palliation in skeletal metastases. Eur J Nucl Med Mol Imaging. 2004,31:S171-S178.
16. Lovera C, Massardo T, Galleguillos MC, et al. Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with samarium 153 ethylendiaminotetramehylenephosphate. Rev Med Chil. 1998;126:963-971.
17. Li L, Liang Z, Deng H, et al. Samarium-153-EDTMP bone uptake rate and its relation to therapeutic effect. Chin Med J. 2002;115:1096-1098.
18. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63:940-945.
19. Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samararium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med. 1999;26:2-7.
20. Serafini AN. Samarium SM-153 lexidronam for the palliation of bone pain associated with metastases. Cancer. 2000;88(suppl):2934-2939.
21. Friedland J. Local and systemic radiation for palliation of metastatic disease. Urol Clin N Am. 1999;26:391-402.
22. Serafini A. Therapy of metastatic bone pain. J Nucl Med. 2001;42:895-906.
23. Menda Y, Bushnell DL, Williams RD, et al. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Clin Nucl Med. 2000;25:698-700.
24. Alberts AS, Smit BJ, Louw WKA, et al. Dose-response relationship and multiple-dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol. 1997;43:175-179.
25. Serafini AN. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastases. Q J Nucl Med. 2001;45:91-99.